LOTUS TISSUE REPAIR
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.
LOTUS TISSUE REPAIR
Industry:
Biotechnology Health Care Medical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.lotustissuerepair.com
Total Employee:
11+
Status:
Closed
Contact:
617-674-7610
Email Addresses:
[email protected]
Total Funding:
26 M USD
Technology used in webpage:
IPv6 Person Schema Cloudflare Hosting Gravatar Profiles Cloudflare DNS
Similar Organizations
Opsonix
Opsonix is a developer of a pathogen-extracting therapy designed to transform the treatment of bloodstream infections and sepsis.
Current Employees Featured
Founder
Investors List
Third Rock Ventures
Third Rock Ventures investment in Series A - Lotus Tissue Repair
Official Site Inspections
http://www.lotustissuerepair.com
- Host name: lb-182-253.above.com
- IP address: 103.224.182.253
- Location: Australia
- Latitude: -33.494
- Longitude: 143.2104
- Timezone: Australia/Sydney
More informations about "Lotus Tissue Repair"
Lotus Tissue Repair - Crunchbase Company Profile
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as …See details»
Lotus Tissue Repair Company Profile 2024: Valuation, Funding ...
Jun 30, 2011 · Information on valuation, funding, cap tables, investors, and executives for Lotus Tissue Repair. Use the PitchBook Platform to explore the full profile. Request a free trial Log inSee details»
Lotus Tissue Repair - VentureRadar
Lotus Tissue Repair, Inc. is developing its proprietary recombinant collagen type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role …See details»
Lotus Tissue Repair, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Lotus Tissue Repair, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial.See details»
Lotus Tissue Repair Inc - Company Profile and News
Lotus Tissue Repair, Inc. develops human skin technologies. The Company produces products to help in chronic wound healing including diabetic foot ulcers and genetic skin diseases.See details»
Lotus Tissue Repair - Company Profile & Staff Directory - ContactOut
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role …See details»
Lotus Tissue Repair - Funding, Financials, Valuation & Investors
Lotus Tissue Repair develops an accelerating chronic wound healing technology for the treatment dermatologic conditions such as foot ulcers.See details»
Lotus Tissue Repair - Overview, News & Similar companies
Lotus Tissue Repair contact info: Phone number: (617) 674-7610 Website: www.fibrx.com What does Lotus Tissue Repair do?See details»
Lotus Tissue Repair - Contacts, Employees, Board Members
Lotus Tissue Repair develops an accelerating chronic wound healing technology for the treatment dermatologic conditions such as foot ulcers.See details»
Lotus Tissue Repair - Products, Competitors, Financials, Employees ...
Lotus Tissue Repair is developing its recombinant collagen type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating …See details»
Shire Acquires Lotus Tissue Repair - genengnews.com
Jan 8, 2013 · Shire said today it will acquire Lotus Tissue Repair, the privately-held developer of the first and only protein replacement therapy now in preclinical development for the orphan …See details»
Lotus Tissue Repair | VentureRadar
Lotus Tissue Repair, Inc. is developing its proprietary recombinant collagen type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role …See details»
Shire Acquires Lotus Tissue Repair, Inc. - PR Newswire
Jan 8, 2013 · Shire plc (LSE: SHP, NASDAQ: SHPG), announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology …See details»
Shire Acquires Lotus Tissue Repair, Inc. - Takeda
Jan 8, 2013 · Shire plc (LSE: SHP, NASDAQ: SHPG), announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology …See details»
Mark de Souza - SonALAsense
He has been a founder, CEO, or Executive Chair of Lotus Tissue Repair (a Third Rock Ventures company acquired by Shire), PellePharm and Molecular Skin Therapeutics (both BridgeBio …See details»
Shire Acquires Lotus Tissue Repair - pharmtech.com
Jan 8, 2013 · Shire has signed an agreement to acquire Lotus Tissue Repair, Inc., a biotechnology company developing the first and only protein replacement therapy for the …See details»
Lotus Tissue Repair, Inc. Secures $26 Million Series A Financing to ...
Jun 30, 2011 · Lotus Tissue Repair, Inc. is developing its proprietary recombinant collagen type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an …See details»
Lotus Tissue Repair Pioneers New Treatment for Rare and
Jun 30, 2011 · Lotus Tissue Repair Inc. has launched as a spinout from Third Rock Ventures, which led the Cambridge biotech’s $26 million Series A funding round. The funds will be used …See details»
New Hope for Children With Devastating Skin Condition - Takeda
Feb 7, 2013 · Recently Shire entered this meaningful research space when it announced its intention to buy Lotus Tissue Repair, a biotech company now in the late pre-clinical stages of …See details»
Lotus Tissue Repair launches with $26M to fight rare skin disease
Jun 30, 2011 · Lotus Tissue Repair Inc. has launched as a spinout from Third Rock Ventures, which led the Cambridge biotech’s $26 million Series A funding round. The funds will be used …See details»